The U.S. Food and Drug Administration (FDA) has issued warning letters to three companies—Bailey’s Wellness LLC (dba Bailey’s CBD), Holista LLC (dba HolistaPet), and House of Alchemy LLC (dba CBD Dog Health and Hamet & Love LLC dba MycoDog)—for marketing unapproved cannabidiol (CBD) products for animals. In letters issued last month, the FDA has determined these products are unapproved new animal drugs that are unsafe under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA’s actions highlight concerns about the safety and efficacy of CBD products for animals, especially those making unsubstantiated health claims. Some CBD dog treats were also considered adulterated under the FD&C Act because CBD is not approved for use in animal food. The FDA highlighted serious food safety concerns, particularly for products intended for food-producing animals, pointing to insufficient research on residue buildup and risks to human health. These warning letters are part of the FDA’s ongoing efforts to regulate the marketing of cannabis-derived products and protect public health. Companies are advised to ensure compliance with the FD&C Act to avoid legal action.
